Definium Therapeutics, Inc. (DFTX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Definium Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Medicinal Chemicals & Botanical Products
High 39.00 at 7:45 am ET, low 38.16 at 12:15 pm ET.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
the bull case· 3
364
managers reporting a position in institutional filings across the latest reporting date
13fJun 30 '261 of 21
largest reporting managers who reduced their stake in the latest quarter
13fJun 30 '26+51.69%
shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 1
39
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Definium Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2833, Medicinal Chemicals & Botanical Products, from each company's own filings. Largest first.
364 managers report a position worth $5.6B between them, and 39 of them hold 80% of it.
tall tick = annual report · 1 on record
DFTX (Definium Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.